Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Oncology and Immunotherapy Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for MICB drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | MICB ECD-Fc / Mutant Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. |
View MICB Products |
| Gene Delivery | MICB Promise-ORF / Lentivirus Full-length ORF for stable cell lines. |
View MICB Products |
| Benchmark Ab | Anti-MICB (Sequence of clinical benchmark clones) Recombinant positive control. |
View MICB Products |
| Validator | MICB siRNA Set For knockdown verification. |
View MICB Products |
| Related Target A | MICA High-homology family member. Crucial for assessing cross-reactivity and pan-MICA/B therapeutic profile. |
View MICA Products |
| Related Target B | NKG2D Cognate activating receptor on NK and T cells. Essential for blocking and functional activation assays. |
View NKG2D Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Shedding Prevention Validation | Lentivirus for stable cell line generation to express full-length membrane-bound MICB for shedding cleavage assays. |
| MICA/MICB Cross-Reactivity | MICA and MICB ortholog and homolog panels strictly verified by mass spectrometry and sequence alignment. |
| Lack of Controls | Clinical Benchmark Antibodies (Biosimilars) included for assay calibration. |
| False Positives | Validated siRNA included for target-specific knockdown verification. |
Live MICB R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The therapeutic targeting of the NKG2D pathway via MICB (MHC class I polypeptide-related sequence B) is an emerging frontier in cancer immunotherapy. Tumor cells frequently escape immune surveillance by shedding surface MICB through metalloproteinase-mediated cleavage, generating soluble MICB (sMICB) which downregulates NKG2D receptors on NK and CD8+ T cells. The race for MICB therapeutics is intensifying, with major players shifting focus from traditional mAbs to monoclonal antibodies that specifically prevent shedding, as well as bispecific/multispecific formats. As first-generation therapies reach the clinic, the next wave of R&D is targeting the preservation of surface MICB density to sustain NK-cell-mediated cytotoxicity.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Anti-Shedding mAb | Academic Institutes, Biotech Startups | Advanced Solid Tumors, Hematological Malignancies | Shedding Inhibition Assay (Need Lentivirus for stable surface expression and recombinant ECD-Fc) |
| Bispecific / NK Engager | Established Biopharma, Immunotherapy Biotechs | Colorectal Cancer, Prostate Cancer | Heterodimer & Receptor Binding Validation (Need high-purity MICB and NKG2D recombinant proteins) |
| CAR-NK / Cell Therapy | Cell Therapy Developers | Refractory Solid Tumors | Target Density & Specificity Assay (Need sequence-verified MICB and MICA for cross-reactivity screening) |